Lund, January 25, 2021 -- Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive results from the initial phase of studying compatibility with a model vaccine technology platform, both companies have now extended the study agreement until June 30, 2021. This is to finalize the analysis of Ziccum’s air-drying capabilities on one of Janssen’s vaccine platform technologies.

“We’re very proud to extend this first pilot project with Janssen”, says Ziccum CEO Göran Conradson.

“The first pilot project collaboration turned out well”,  Ziccum’s Chairman Fredrik Sjövall points out. “We are of course delighted that we are now extending this collaboration.”

LaminarPaceTM enables the air-drying of delicate biologic drugs such as proteins, peptides and vaccines at room temperature, keeping the active ingredient intact. This capability could enable the development of new, stable, dry powder formulations of vaccines and biologic therapies that can be transported and administered cost-effectively to any climate in the world. In this extended collaboration each party covers their own costs.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
Mail: conradson@ziccum.com
Mobile: +46 709 61 55 99
 
Certified Adviser
Erik Penser Bank AB
Mail: certifiedadviser@penser.se
Phone: +46 8 463 83 00

About Ziccum

Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.

This information is information that Ziccum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-01-25 18:40 CET.

Attachments

Ziccum extends evaluation agreement with global pharmaceutical company

© Modular Finance, source Nordic Press Releases